Drug Trial Radar · NCT02453061
A Comparative Phase 2 Study Assessing the Efficacy of Triheptanoin, an Anaplerotic Therapy in Huntington's Disease
Last checked: Nov 20, 2026Latest source record: Jun 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
100
Actual
Start
Jun 29, 2015
Primary completion
Dec 3, 2019
Study completion Dec 3, 2019
Sponsor
- Lead sponsor
- Institut National de la Santé Et de la Recherche Médicale, FranceGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- Collaborators
- Ultragenyx Pharmaceutical Inc
- First posted
- May 25, 2015
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In the study the investigators plan to include 100 early affected HD patients (5 ≤ UHDRS ≤ 40) in a randomized, double-blind, controlled study in 2 centers (France and the Netherlands). Patients will receive either triheptanoin at 1g/kg of body weight per day (n = 50), or a control oil (n = 50) at 1g/kg of body weight per day for 6 months followed by an open label phase using triheptanoin for another 6 months. Efficacy of triheptanoin will be evaluated by measurements of caudate volume using volumetric magnetic resonance imaging. Clinical improvement will be evaluated by brain energy metabolism quantification as evaluated by the ratio of inorganic phosphate/phosphocreatine, during visual stimulation, using 31P-MRS, UHDRS, TFC, and PBA-S scores as well as performance on the neuropsychological battery. Patient quality of life will be evaluated with the SF-36 questionnaire before and after treatment; biological tolerance and compliance will be evaluated by routine biochemical blood tests, plasma and urine measurements of triheptanoin oil derivatives and patient report.
Conditions
- Huntington Disease
Interventions
Triheptanoin oilDrug
Triheptanoin oil orally administered at 1g/kg/day
PlaceboDrug
Safflower oil orally administered at 1g/kg/day
Primary outcomes
What the sponsor says the trial is designed to measure.
- volumetric magnetic resonance imagingTime frame: 6 months
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
Département de Génétique
Paris, France
Department of Neurology
Leiden, Netherlands
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.